HTT and Huntington disease: One study reported that in the R6/2 transgenic mouse model of HD, in which exon 1 of a mutated human HTT gene is expressed and driven by the human huntingtin promoter [68], treatment with Necrostatin-1 ameliorated symptoms and delayed disease progression, thus identifying a role for RIPK1 in disease progression [69].